← Back to Search

Other

LY3437943 for Obesity

Verified Trial

Phase 2

Waitlist Available

Research Sponsored by Eli Lilly and Company

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 48

Summary

This trial is testing a new medication called LY3437943 to help people who are obese or overweight lose weight. The study will last over a year and involve multiple visits. The medication works by affecting the body's metabolism and appetite to promote weight loss.

Eligible Conditions

Obesity

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 48

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 48

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 48 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Secondary study objectives

Mean Change From Baseline in BMI

Mean Change From Baseline in Body Weight

Mean Change From Baseline in Waist Circumference

+4 more

Side effects data

From 2022 Phase 2 trial • 281 Patients • NCT04867785

20%

Decreased appetite

20%

Nausea

15%

Diarrhoea

11%

Constipation

11%

Vomiting

11%

Upper respiratory tract infection

11%

Urinary tract infection

Fatigue

Dyspepsia

Anaemia

Covid-19

Lipase increased

Dizziness

Weight decreased

Cellulitis

Diabetic ketoacidosis

Abdominal pain

Eructation

Headache

100%

80%

60%

40%

20%

Study treatment Arm

12 mg LY3437943 (2 mg)

8 mg LY3437943 (2 mg)

Placebo

1.5 Milligram (mg) Dulaglutide

0.5 mg LY3437943

4 mg LY3437943 (2 mg)

4 mg LY3437943 (4 mg)

8 mg LY3437943 (4 mg)

Trial Design

7Treatment groups

Experimental Treatment

Placebo Group

Group I: 8 mg LY3437943 (4 mg)Experimental Treatment1 Intervention

Participants received 4 mg LY3437943 starting dose followed by 8 mg LY3437943 administered as SC injection QW.

Group II: 8 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 and then 8 mg LY3437943 administered as SC injection QW.

Group III: 4 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943 administered as SC injection QW.

Group IV: 4 mg LY3437943Experimental Treatment1 Intervention

Participants received 4 mg LY3437943 administered as SC injection QW.

Group V: 12 mg LY3437943 (2 mg)Experimental Treatment1 Intervention

Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW.

Group VI: 1 milligram (mg) LY3437943Experimental Treatment1 Intervention

Participants received 1 mg LY3437943 administered as SC injection QW.

Group VII: PlaceboPlacebo Group1 Intervention

Participants received placebo matched to LY3437943 administered as subcutaneous (SC) injection once-weekly (QW).

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

LY3437943

2022

Completed Phase 2

~1090